Literaturnachweis - Detailanzeige
| Autor/inn/en | Shurtz, Logan; Schwartz, Chloe; DiStefano, Charlotte; McPartland, James C.; Levin, April R.; Dawson, Geraldine; Kleinhans, Natalia M.; Faja, Susan; Webb, Sara J.; Shic, Frederick; Naples, Adam J.; Seow, Helen; Bernier, Raphael A.; Chawarska, Katarzyna; Sugar, Catherine A.; Dziura, James; Senturk, Damla; Santhosh, Megha; Jeste, Shafali S. |
|---|---|
| Titel | Concomitant Medication Use in Children with Autism Spectrum Disorder: Data from the Autism Biomarkers Consortium for Clinical Trials |
| Quelle | In: Autism: The International Journal of Research and Practice, 27 (2023) 4, S.952-966 (15 Seiten)
PDF als Volltext |
| Zusatzinformation | ORCID (Shurtz, Logan) ORCID (Faja, Susan) |
| Sprache | englisch |
| Dokumenttyp | gedruckt; online; Zeitschriftenaufsatz |
| ISSN | 1362-3613 |
| DOI | 10.1177/13623613221121425 |
| Schlagwörter | Autism Spectrum Disorders; Drug Therapy; Incidence; Child Behavior; Research Methodology; Behavior Problems; Hyperactivity; Personality Traits; Children; Preadolescents; Individual Characteristics; Massachusetts (Boston); California (Los Angeles); Washington; North Carolina; Connecticut (New Haven); Vineland Adaptive Behavior Scales; Aberrant Behavior Checklist |
| Abstract | Children with autism spectrum disorder are prescribed various medications to address behavior and mood. In clinical trials, individuals taking concomitant psychotropic medications often are excluded to maintain homogeneity and prevent contamination of clinical endpoints. However, this choice may compromise the representativeness of the sample. In a recent study designed to identify biomarkers and endpoints for clinical trials (the Autism Biomarkers Consortium for Clinical Trials), school-age children with autism spectrum disorder were enrolled without excluding for medications, providing the opportunity to examine characteristics of psychotropic medication use and guide future decisions on medication-related inclusion criteria. The aims of the current analysis were (1) to quantify the frequency and type of psychotropic medications reported in school-age children enrolled in the study and (2) to examine behavioral features of children with autism spectrum disorder based on medication classes. Of the 280 children with autism spectrum disorder in the cohort, 42.5% were taking psychotropic medications, with polypharmacy in half. The most commonly reported psychotropic medications included melatonin, stimulants, selective serotonin reuptake inhibitors, alpha agonists, and antipsychotics. Our findings suggest that exclusion of children taking concomitant psychotropic medications could limit the representativeness of the study population, perhaps even excluding children who may most benefit from new treatment options. (As Provided). |
| Anmerkungen | SAGE Publications. 2455 Teller Road, Thousand Oaks, CA 91320. Tel: 800-818-7243; Tel: 805-499-9774; Fax: 800-583-2665; e-mail: journals@sagepub.com; Web site: https://sagepub.com |
| Erfasst von | ERIC (Education Resources Information Center), Washington, DC |
| Update | 2024/1/01 |
Literaturbeschaffung und Bestandsnachweise in Bibliotheken prüfen
Permalink als QR-Code
Inhalt auf sozialen Plattformen teilen (nur vorhanden, wenn Javascript eingeschaltet ist)
Teile diese Seite:
